A Phase 2 interventional study of XL184 in Glioblastoma Multiforme, sponsored by Exelixis. Completed at 8 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-05.
Sponsored by Exelixis · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,302 studies in Glioblastoma with a site in United States — 194 open to participants now, 324 under way, 16 of them phase 3. Glioblastoma · United States.
Among the 1,302 studies in Glioblastoma with a site in United States, this one is the 57th largest by enrollment of the 1,155 interventional ones that give a count, is one of 49 that started in 2008, is one of 396 in phase 2, and was the 336th registered.
2,135 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.
Browse Glioblastoma studies →194 of the 1,302 studies in Glioblastoma with a site in United States are open now. Recruiting first, the newest first:
Macarena De La Fuente, MD · Sites in United States
Ages 18+
Alpheus Medical, Inc. · Sites in United States
Ages 18–80
Beijing Inno Medicine Co., Ltd. · Sites in United States, China
Ages 18–70
City of Hope Medical Center · Sites in United States
Ages 18+ · Healthy volunteers
Inova Health Care Services · Sites in United States
Ages 18–98
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 338 Glioblastoma studies recruiting now, 233 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,302 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 671 · Phase 2 592 · Phase 3 55 · Phase 4 4
First in 1979; this study’s year is marked. 49 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 222 is above the median of 36 across 1,756 interventional studies indexed under Glioblastoma.
Median enrollment 33 across the 1,155 interventional studies, 60 across the 79 observational. Of the 882 that completed or were terminated, 344 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
321 of 1,302 have an industry lead sponsor. The 10 most frequent:
Exelixis is the lead sponsor of 57 studies on the registry; 11 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Exelixis has 3 studies filed under Glioblastoma — fewer than ten, so there is no comparison to draw.
105 of the studies in Glioblastoma with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05271240Phase 3Northwell HealthRepeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM | 2027-04-01 |
| NCT03743662Memorial Sloan Kettering Cancer CenterNivolumab With Radiation Therapy and Bevacizumab for Recurrent MGMT Methylated Glioblastoma | 2026-11 |
| NCT04574856University of Michigan Rogel Cancer CenterMultiparametric MR-Guided High Dose Adaptive Radiotherapy With Concurrent Temozolomide in Patients With Newly Diagnosed Glioblastoma | 2026-11-19 |
| NCT02704858Neonc Technologies, Inc.Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma | 2026-11-30 |
| NCT05781321Mayo ClinicShort Course Radiotherapy for the Treatment of Patients With Glioblastoma, SAGA Study | 2026-11-30 |
Add all 105 to your calendar (.ics) → With an account.
Among the 1,302 studies in Glioblastoma with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the objective response rate and 6-month progression-free survival rate of XL184 in subjects with recurrent or progressive glioblastoma multiforme. XL184 is a new chemical entity that inhibits VEGFR2, MET and RET, kinases implicated in tumor formation, growth and migration.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
cabozantinib, 175 mg, taken orally once per day (qd).
Drug: XL184
cabozantinib, 125 mg, taken orally once per day (qd).
Drug: XL184
cabozantinib, 125 mg, taken orally once per day (qd).
Drug: XL184
Gelatin capsules supplied in 25-mg and 100-mg strengths; continuous daily dosing
Objective Response Rate (ORR)
Response and progression were determined per modified MacDonald Criteria and modified RANO criteria for GBM using imaging and clinical features
Time frame: 8 weeks until progressive disease
Duration of Objective Response (Months)
Duration of response is defined as the time from the first documentation of objective response that was subsequently confirmed at a visit that was ≥ 28 days later to disease progression or death due to any cause.
Time frame: Assessed during periodically scheduled visits until progressive disease
Progression Free Survival (PFS)
Response and progression were determined per modified MacDonald Criteria and modified RANO criteria for GBM using imaging and clinical features
Time frame: Assessed during periodically scheduled visits until progressive disease
Overall Survival (OS)
Overall survival (OS) is defined as the time from first dose to death due to any cause.
Time frame: Assessed during periodically scheduled visits until progressive disease
| Milestone | Treatment Group A (175 mg) | Treatment Group B (125 mg) | Treatment Group C (125 mg) |
|---|---|---|---|
| Started | 46 | 59 | 117 |
| Naïve | 34 | 37 | 81 |
| Pre-treated | 12 | 22 | 36 |
| Completed | 0 | 0 | 0 |
| Not completed | 46 | 59 | 117 |
| Withdrew: Adverse event | 11 | 8 | 22 |
| Withdrew: Death | 0 | 0 | 1 |
| Withdrew: Physician decision | 0 | 2 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 3 |
| Withdrew: Disease progression--per modified macdonald criteria (group a) | 30 | 0 | 0 |
| Withdrew: Disease progression--radiologic progression (group b and c) | 0 | 42 | 76 |
| Withdrew: Disease progression--clinical deterioration | 3 | 6 | 11 |
| Withdrew: Roll-over to another study | 1 | 0 | 4 |
| Withdrew: Other--subject had intracranial hemorrhage | 1 | 0 | 0 |
| Milestone | Treatment Group A (175 mg) | Treatment Group B (125 mg) | Treatment Group C (125 mg) |
|---|---|---|---|
| Started | 46 | 59 | 117 |
| Completed | 0 | 0 | 0 |
| Not completed | 46 | 59 | 117 |
| Withdrew: Death | 41 | 50 | 93 |
| Withdrew: Lost to follow-up | 0 | 2 | 1 |
| Withdrew: Withdrawal by subject | 0 | 2 | 2 |
| Withdrew: Various reasons | 5 | 5 | 21 |
Response and progression were determined per modified MacDonald Criteria and modified RANO criteria for GBM using imaging and clinical features
| percentage of participants | Treatment Group A1 (175 mg) - Naive | Treatment Group B1 (125 mg) - Naive | Treatment Group C1 (125 mg) - Naive | Treatment Group A2 (175 mg) - Pre-Treated | Treatment Group B2 (125 mg) - Pre-Treated | Treatment Group C2 (125 mg) - Pre-Treated |
|---|---|---|---|---|---|---|
| Objective Response Rate (ORR) | 17.6 | 27.0 | 8.8 | 8.3 | 0 | 5.6 |
Duration of response is defined as the time from the first documentation of objective response that was subsequently confirmed at a visit that was ≥ 28 days later to disease progression or death due to any cause.
| Months | Treatment Group A1 (175 mg) - Naive | Treatment Group B1 (125 mg) - Naive | Treatment Group C1 (125 mg) - Naive | Treatment Group A2 (175 mg) - Pre-Treated | Treatment Group B2 (125 mg) - Pre-Treated | Treatment Group C2 (125 mg) - Pre-Treated |
|---|---|---|---|---|---|---|
| Duration of Objective Response (Months) | 5.913 (2.760 to 12.812) | 8.541 (3.778 to 9.264) | NA (2.792 to NA) | NA (NA to NA) | — | 4.172 (NA to NA) |
Response and progression were determined per modified MacDonald Criteria and modified RANO criteria for GBM using imaging and clinical features
| Months | Treatment Group A1 (175 mg) - Naive | Treatment Group B1 (125 mg) - Naive | Treatment Group C1 (125 mg) - Naive | Treatment Group A2 (175 mg) - Pre-Treated | Treatment Group B2 (125 mg) - Pre-Treated | Treatment Group C2 (125 mg) - Pre-Treated |
|---|---|---|---|---|---|---|
| Progression Free Survival (PFS) | 3.712 (1.905 to 5.092) | 4.698 (3.647 to 9.231) | 3.712 (2.562 to 3.712) | 3.285 (0.953 to NA) | 1.807 (1.675 to 3.745) | 2.300 (2.201 to 2.464) |
Overall survival (OS) is defined as the time from first dose to death due to any cause.
| Months | Treatment Group A (175 mg) - Naive | Treatment Group A (175 mg) - Pre-Treated | Treatment Group B (125 mg) - Naive | Treatment Group B (125 mg) - Pre-Treated | Treatment Group C (125 mg) - Naive | Treatment Group C (125 mg) - Pre-Treated |
|---|---|---|---|---|---|---|
| Overall Survival (OS) | 7.671 (5.913 to 13.502) | 4.074 (1.380 to 16.689) | 10.381 (7.260 to 16.393) | 4.221 (1.971 to 5.716) | 10.217 (8.016 to 12.122) | 4.583 (2.792 to 5.683) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment Group A (175 mg) | 41/46 (89.1%) | 24/46 (52.2%) | 46/46 (100%) |
| Treatment Group B + Group C (125 mg) | 144/176 (81.8%) | 90/176 (51.1%) | 176/176 (100%) |
| Event | Treatment Group A (175 mg) | Treatment Group B + Group C (125 mg) |
|---|---|---|
| ConvulsionNervous system disorders | 6/46 | 13/176 |
| Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders | 2/46 | 12/176 |
| DiarrhoeaGastrointestinal disorders | 3/46 | 2/176 |
| Confusional StatePsychiatric disorders | 3/46 | 4/176 |
| Deep Vein ThrombosisVascular disorders | 0/46 | 10/176 |
| HemiparesisNervous system disorders | 0/46 | 8/176 |
| NauseaGastrointestinal disorders | 2/46 | 3/176 |
| Wound DehiscenceInjury, poisoning and procedural complications | 2/46 | 3/176 |
| Troponin I IncreasedInvestigations | 2/46 | 0/176 |
| DehydrationMetabolism and nutrition disorders | 1/46 | 6/176 |
| Event | Treatment Group A (175 mg) | Treatment Group B + Group C (125 mg) |
|---|---|---|
| FatigueGeneral disorders | 35/46 | 132/176 |
| DiarrhoeaGastrointestinal disorders | 31/46 | 97/176 |
| Decreased AppetiteMetabolism and nutrition disorders | 22/46 | 66/176 |
| ConstipationGastrointestinal disorders | 22/46 | 54/176 |
| HeadacheNervous system disorders | 20/46 | 59/176 |
| HypertensionVascular disorders | 18/46 | 56/176 |
| DysphoniaRespiratory, thoracic and mediastinal disorders | 18/46 | 49/176 |
| NauseaGastrointestinal disorders | 17/46 | 65/176 |
| Palmar-Plantar Erythrodysaesthesia SyndromeSkin and subcutaneous tissue disorders | 17/46 | 56/176 |
| StomatitisGastrointestinal disorders | 17/46 | 31/176 |
| Age, Customized(Participants) | Treatment Group A (175 mg) | Treatment Group B + Group C (125 mg) | Total |
|---|---|---|---|
| 18 to <45 | 11 | 33 | 44 |
| 45 to <55 | 11 | 53 | 64 |
| 55 to <65 | 18 | 61 | 79 |
| 65 to <75 | 6 | 28 | 34 |
| >= 75 | 0 | 1 | 1 |
| Sex: Female, Male(Participants) | Treatment Group A (175 mg) | Treatment Group B + Group C (125 mg) | Total |
|---|---|---|---|
| Female | 15 | 68 | 83 |
| Male | 31 | 108 | 139 |
| Race (NIH/OMB)(Participants) | Treatment Group A (175 mg) | Treatment Group B + Group C (125 mg) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 2 | 2 |
| Asian | 1 | 4 | 5 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 3 | 5 | 8 |
| White | 40 | 158 | 198 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 2 | 7 | 9 |
The record gives a start of May 2008, a primary completion of Jun 2012 and a completion of Dec 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2024, 11 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cabozantinib